ANP presenting now, page-44

Mark did mention few times about Sarepta (only DMD drugs with not so effective/gene therapy trial failure), yet have 0.5 billion revenue/year and with market capital approximately USD 6billion.

With Professor Voit (DMD Expert) as our Principal Investigator for Phase IIB trial in Europe, you can be 100% certain that we'll get accelerated approval after 12 months dosing.

He mentioned again Dr. Charmaine Gittleson came from a Big Pharmaceutical company like CSL to now join a small biotech company like us that the market should take note of. As Timothy Wong (Spark Plus Corporate Finance Advisor) said "A Big Signal" !

So, you don't think we can be the next Sarepta or even better than Sarepta? (Note: Sarepta only have DMD drugs, but we are going to have DMD and other multiple rare disease drugs in our product pipeline very soon).. Indeed, very exciting time ahead!